Details for New Drug Application (NDA): 218054
✉ Email this page to a colleague
The generic ingredient in REGADENOSON is regadenoson. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the regadenoson profile page.
Summary for 218054
| Tradename: | REGADENOSON |
| Applicant: | Indies Pharma |
| Ingredient: | regadenoson |
| Patents: | 0 |
Pharmacology for NDA: 218054
| Mechanism of Action | Adenosine Receptor Agonists |
Suppliers and Packaging for NDA: 218054
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 218054 | ANDA | Marlex Pharmaceuticals, Inc. | 10135-803 | 10135-803-51 | 1 SYRINGE in 1 CARTON (10135-803-51) / 5 mL in 1 SYRINGE |
| REGADENOSON | regadenoson | SOLUTION;INTRAVENOUS | 218054 | ANDA | Indies Pharma Jamaica Limited | 83032-001 | 83032-001-02 | 1 SYRINGE in 1 CARTON (83032-001-02) / 5 mL in 1 SYRINGE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 0.4MG/5ML (0.08MG/ML) | ||||
| Approval Date: | Aug 22, 2024 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
